Maximal antagonist effect in nicotine-treated rats
| Antagonist | Elevations in Reward Thresholds (% of baseline) | Dose | Somatic Signs (overall number) | Dose | Place Aversion (change in time—s) | Dose |
|---|---|---|---|---|---|---|
| Mecamylamine (s.c.) | 146 | 3.43 mg/kg | 75 | 3.43 mg/kg | −141 | 4.0 mg/kg |
| DHβE (s.c.) | 138 | 6.0 mg/kg | 11 | 6.0 mg/kg | −111 | 10.0 mg/kg |
| Chlorisondamine (s.c.) | 112 | 1.0 mg/kg | 57 | 1.0 mg/kg | n/a | n/a |
| Chlorisondamine (i.c.v.) | 133 | 10 μg | 42 | 10 μg | n/a | n/a |
| Naloxone (s.c.) | 116 | 2.0 mg/kg | 22 | 8.0 mg/kg | −102 | 0.12 mg/kg |
Maximal effects of nicotinic antagonists and an opioid antagonist on reward thresholds, somatic signs, and place aversions in nicotine-treated rats expressed as a percentage of the mean 5-day baseline threshold, mean overall number of signs observed during a 10-min observation, and the mean difference in time (seconds) spent in the antagonist-paired compartment before conditioning compared to after conditioning, respectively.
n/a, not applicable.